Put companies on watchlist
urban-gro, Inc
ISIN: US91704K2024
WKN: A2QN2U
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

urban-gro, Inc · ISIN: US91704K2024 · EQS - Analysts (6 News)
Country: Germany · Primary market: United States of America · EQS NID: 19323
04 April 2024 04:41PM

Kaufen


Original-Research: urban-gro, Inc - from First Berlin Equity Research GmbH

Classification of First Berlin Equity Research GmbH to urban-gro, Inc

Company Name: urban-gro, Inc
ISIN: US91704K2024

Reason for the research: Jahresergebnisse Recommendation: Kaufen
from: 04.04.2024
Target price: $4,30
Target price on sight of: 12 Monate
Last rating change: -
Analyst: Ellis Acklin

First Berlin Equity Research hat ein Research Update zu urban-gro, Inc. (ISIN: US91704K2024) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und senkt das Kursziel von USD 4,70 auf USD 4,30.

Zusammenfassung:
Trotz eines erheblichen Umsatz- und EBITDA-Rückgangs in Q4 behalten wir unsere Kaufempfehlung für UGRO bei. Das vierte Quartal war reines Pech, als drei kommerzielle Projekte, die bis JE23 fertiggestellt werden sollten, in das Jahr 2024 verschoben wurden. Die Anleger reagierten auf die Nachricht mit Verkäufen, aber wir sind der Meinung, dass sich der drastische Aktienkursrückgang bereits bei der Q1-Berichterstattung als Überreaktion erweisen könnte. Das Management von UGRO betonte, dass die Projekte nicht verloren seien und in Q1 wieder aktiv waren, während es gleichzeitig bekräftigt hat, dass das Unternehmen 2024 ein schwarzes AEBITDA erreichen will. Die erste Guidance für 2024 unterstreicht die Notwendigkeit, konservativ zu sein und die Glaubwürdigkeit bei den Investoren wiederherzustellen. In der Zwischenzeit bleiben auch potenzielle legislative Katalysatoren für amerikanisches Cannabis im Spiel. Nach Anpassung unserer Prognosen für den Jahresbericht 2023 ist unser Kursziel nun $4,30 (zuvor: $4,70).

First Berlin Equity Research has published a research update on urban-gro, Inc. (ISIN: US91704K2024). Analyst Ellis Acklin reiterated his BUY rating and decreased the price target from USD 4.70 to USD 4.30.

Abstract:
We are staying Buy-rated on UGRO, despite a substantial Q4 topline and EBITDA miss. The company was snake-bitten in Q4, when three commercial projects slated for YE completion pushed into 2024. Investors hit the bid on the shortfall, but we think the sharp stock recoil may prove to be an overreaction as soon as Q1 reporting. UGRO brass emphasised that the projects were not lost and were active in Q1, while also recommitting to achieve a black AEBITDA in 2024. The initial 2024 guide underpins the need to be conservative and restore credibility with investors. Meanwhile, potential legislative catalysts for American cannabis also remain in play. Our TP moves to $4.3 (old: $4.7) after recalibrating FBe on 2023 reporting.

Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses siehe die vollständige Analyse.

You can download the research here:
http://www.more-ir.de/d/29323.pdf

Contact for questions
First Berlin Equity Research GmbH
Herr Gaurav Tiwari
Tel.: +49 (0)30 809 39 686
web: www.firstberlin.com
E-Mail: g.tiwari@firstberlin.com

-------------------transmitted by EQS Group AG.-------------------

The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.

Visual performance / price development - urban-gro, Inc
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.